News | December 06, 2006

Longer Use of Clopidogrel Explored

Taking anti-platelet medication longer than current recommendations may lower heart attack or death risks for patients with drug-eluting stents, according to a study funded by the Agency for Healthcare Research and Quality and published this week in the online version of JAMA.

Clopidogrel is currently recommended for three to six months after placement of DES. But the new observational study by AHRQ's DEcIDE Research Center at Duke University suggests the drug reduces risks of heart attack or death for at least two years in some patients, Newswire reports.

"This study suggests that patients and their physicians should consider extending the period of use of this therapy while monitoring its effects very carefully,'' said AHRQ Director Carolyn M. Clancy, MD. "Further research will help us understand fully the balance of risks and benefits of extended use of anti- platelet therapy in people who have drug-eluting stents."

How long clopidogrel may be needed, however, remains uncertain.

The Duke study included 4,666 patients who received drug-eluting stents or bare metal stents during a five-year period. Of those, 3,609 were defined as "event free,'' meaning they had not died, had heart attacks or undergone additional procedures to open coronary arteries for at least six months since stent placement. Researchers then checked those patients' use of clopidogrel and their health status through September 2006. The study concluded:

-- Among drug-eluting stent patients who were event free at six months, those who reported clopidogrel use were significantly less likely to die during the next 18 months than those who did not use the drug (a 2 percent death rate vs. a 5.3 percent death rate). These patients were also less likely to either die or have a heart attack (3.1 percent vs. 7.2 percent).

-- Among patients who had been event free for a full year, those who reported clopidogrel use at 12 months were similarly less likely than those not taking clopidogrel to die during the next 12 months (0 percent vs. 3.5 percent), and less likely to either die or have a heart attack (0 percent vs. 4.5 percent).

For more information about DEcIDE and the EHC program, visit http://www.effectivehealthcare.ahrq.gov.

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init